Approved Study Database

Ref. No. Scientific Title Principal investigator
2008.159 A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-Positive Systemic Lupus Erythematosus Patients with Active Disease Who Participated in Study SL0007 Asso. Prof. TAM Lai Shan
2007.486 A Double-blind, Randomized, Placebo-control Trial to Assess the Effects of Hydroxychloroquine on Progression of Carotid Artery Intimal-Medial Thickening in Psoriatic Arthritis Ms Tam Lai Shan
2008.160 SERAPHIN: Study with Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome Prof Tam Lai Shan
2008.161 SERAPHIN-OL: Study with An ERA in Pulmonary Arterial Hypertension to Improve Clinical Outcome (Open Label) – Long-term Single-arm Open-label Extension Study of the SERAPHIN study, to Assess the Safety and Tolerability of ACT-064922 in Patients with Symptomatic Pulmonary Arterial Hypertension Prof. TAM Lai Shan
2013.470 A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA) Prof Tam Lai Shan
2010.056 Effect of anti-TNF Prof. TAM LAI SHAN
2014.082 A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects with Lupus Nephritis Prof. TAM Lai Shan
2012.007 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis Prof. TAM Lai Shan
2009.409 Traditional Chinese Medicine for Osteoarthritis of the Knee (TCM-OAK): A dose escalation study Prof. Tam Lai Shan
2010.491 Effect of early intensive treatment in patients with recent-onset rheumatoid arthritis Prof. TAM Lai Shan
2013.568 A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with ankylosing spondylitis. Prof. TAM Lai Shan
2009.429 A Phase 2A, Randomized, Double-Blind, Active and Placebo-Controlled Study of PF-04171327 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis Dr. TAM Lai Shan
2014.167 Exploiting the immunomodulatory and anti-inflammatory role of IL35 to modulate inflammation and autoreactive B cell activation in rheumatoid arthritis Prof. TAM Lai Shan
2008.344 Premature Atherosclerosis in Early Rheumatoid Arthritis Prof Tam Lai Shan
2008.343 The Chinese University of Hong Kong Early Arthritis Study Prof Tam Lai Shan
2011.541 A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients with Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy Prof. Tam Lai Shan
2008.391 A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), A Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057 Prof. TAM Lai Shan
2012.200 A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus Prof. TAM Lai Shan
2011.378 A Phase 3, Multicenter, Open-Label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (EMBODY 4) Prof. TAM Lai Shan
2012.476 Alteration in bone density and microstructure in early rheumatoid arthritis and its relationship with bone erosion: A one-year study by HR-pQCT and MRI Prof. TAM Lai Shan
2012.559 A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF-α antagonists Prof. TAM Lai Shan
2012.558 An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with mild to moderate systemic lupus erythematosus Professor Tam Lai Shan
2011.542 A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia Prof. Tam Lai Shan
2012.557 A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab Prof. TAM Lai Shan
2011.483 Effect of treat-to-target strategies aiming at remission compared with minimal disease activity on arterial stiffness in early rheumatoid arthritis - a randomized controlled study Prof. TAM Lai Shan
2011.510 Comparison of the effect of denosumab and alendronate on bone density and microarchitecture in rheumatoid arthritis females with low bone mass: A randomized controlled trial Prof. Tam Lai Shan
2017.261 The impact of nurse-led programme with and without statin treatment base on traditional cardiovascular risk score or carotid ultrasound on addressing cardiovascular risk in patients with arthritis: a prospective, multicentre, randomised, controlled trial Prof. TAM Lai Shan
2016.533 A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Prof. TAM Lai Shan
譚麗珊
2015.664 A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs Prof. TAM Lai Shan
譚麗珊
2014.052 Advanced 3-D Bioimaging Technology to improve vertebral fracture prediction in patients with glucocorticoid-induced osteoporosis Prof. TAM Lai Shan
2016.551 A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison with Mycophenolate Mofetil and Corticosteroids in Subjects with Class III/IV±V Lupus Nephritis Prof. TAM Lai Shan
譚麗珊
2017.146 Circulating microRNAs as biomarkers for predicting the early development, repair and progression of bone erosions in early rheumatoid arthritis using HR-pQCT Prof. TAM Lai Shan
譚麗珊
2014.618 Advanced 3-D Bioimaging Technology to assess efficacy of tight- control treatment strategies aiming at SDAI vs DAS remission in the prevention of bone loss in patients with early rheumatoid arthritis Prof. Tam Lai Shan
2015.697 Freely circulating microRNAs as biomarkers for fracture and bone loss in female patients with systemic lupus erythematosus on long-term glucocorticoid therapy Prof. TAM Lai Shan
譚麗珊
2016.037 Identification and validation of microRNAs associated with inflammation detected by magnetic resonance imaging in patients with early rheumatoid arthritis. Prof. TAM Lai Shan
譚麗珊
2016.451 Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using secukinumab Prof. TAM Lai Shan
譚麗珊
2016.450 Cost Effectiveness Analysis of Biologic Therapies for the Treatment of Rheumatoid Arthritis in Hong Kong Prof. TAM Lai Shan
譚麗珊教授
2014.343 Adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQOL) and Psoriatic Arthritis Quality of Life (PsAQOL) questionnaires in Hong Kong Prof. TAM Lai Shan
2017.446 A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis Prof. TAM Lai Shan
譚麗珊
2015.334 Characterization of the potential role of interleukin-36 (IL-36) in regulating protective and pathogenic B cells in systemic lupus erythematosus Dr. TAM Lai Shan
譚麗珊
2016.431 Effect of RANKL inhibition on healing of bone erosion in rheumatoid arthritis using HR-pQCT Prof. TAM Lai Shan
譚麗珊
2013.469 The Clinical Rheumatology Systematic Treat-to-target in Asia Leadership (CRYSTAL) Project Prof. TAM Lai Shan
2016.390 Assessment of structure changes after 4 years on the second and third metacarpophalangeal joint and distal radius in patients with psoriatic arthritis – a follow-up study using High-resolution peripheral quantitative CT (HR-pQCT) Prof. TAM Lai Shan
譚麗珊
2014.387 Coronary atherosclerosis in psoriatic arthritis Prof. TAM Lai Shan
2016.366 MicroRNAs as biomarkers for predicting the effect of anti-TNF and anti-IL6 in changes of bone erosions in rheumatoid arthritis using HR-pQCT Prof. TAM Lai Shan
譚麗珊
2015.214 Prevalence and risk factors for osteoporosis in patients with ankylosing spondylitis in Hong Kong: a cross-sectional cohort study Dr. TAM Lai Shan
譚麗珊
2016.359 A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active lupus nephritis Prof. TAM Lai Shan
譚麗珊教授
2015.065 Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis Prof. TAM Lai Shan
2013.451 Immunopathological roles of the novel inflammatory cytokine interleukin-36 in the patients with systemic lupus erythematous Professor TAM Lai Shan
2013.300 Immunopathological roles of the novel anti-inflammatory cytokine interleukin-35 in the patients with systemic lupus erythematous Prof. TAM Lai Shan

Page 217 of 289.